Vertex Pharmaceuticals Inc / Ma
VRTX· Manufacturing· Fiscal year ends in December
Reshma Kewalramani is the CEO of Vertex Pharmaceuticals Inc / Ma and was paid $21.1M in FY2025 (Dec), down 2%.
Executives6
See all- 1Reshma KewalramaniCEO and PresidentFY2025
- 2Stuart A. ArbuckleEVP & Chief Operating OfficerFY2025
- 3Charles F. Wagner, Jr.EVP & Chief Financial OfficerFY2025
- 4Nia TatsisEVP & Chief Regulatory and Quality OfficerFY2025
- 5Amit SachdevEVP & Chief Patient and External Affairs OfficerFY2025
- 6Carmen BozicEVP & Chief Medical OfficerFY2025
Named executives and their total pay, from the Summary Compensation Table of the latest proxy.
Pay
See allVertex Pharmaceuticals Inc / Ma paid its 6 named executives $59.8M in total in FY2025 (Dec). CEO Reshma Kewalramani was paid $21.1M of that.
| Name | |||
|---|---|---|---|
| Reshma KewalramaniCEO and President | |||
| Stuart A. ArbuckleEVP & Chief Operating Officer | |||
| Charles F. Wagner, Jr.EVP & Chief Financial Officer | |||
| Nia TatsisEVP & Chief Regulatory and Quality Officer | Not disclosed | ||
| Amit SachdevEVP & Chief Patient and External Affairs Officer | Not disclosed | Not disclosed | |
| Carmen BozicEVP & Chief Medical Officer | Not disclosed | Not disclosed |
of each named executive, from the Summary Compensation Table of each proxy.
Peers12
See allThe FY2024 (Dec) proxy of Vertex Pharmaceuticals Inc / Ma names 12 peer companies for pay. Among Vertex Pharmaceuticals Inc / Ma and these peers, CEO pay was 5th highest of 9 and total shareholder return was 5th highest of 9.
5th highest of 9in Vertex Pharmaceuticals Inc / Ma and its pay peers, FY2024 (Dec) by CEO pay:
5th highest of 9in Vertex Pharmaceuticals Inc / Ma and its pay peers, FY2024 (Dec) by total shareholder return:
The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year.
Board8
See all- Jeffrey LeidenChair · 16 yr on the boardNot independent—Paid as an executive
- Alan GarberDirector · 8 yr on the boardIndependentCorporate Governance and Nominating, Science and Technology—Paid as an executive
- Lloyd CarneyDirector · 6 yr on the boardIndependentAudit and Finance (Chair), Corporate Governance and Nominating (Chair)—Paid as an executive
- Diana L. McKenzieDirector · 5 yr on the boardIndependentAudit and Finance, Management Development and Compensation—Paid as an executive
- Michel LagardeDirector · 2 yr on the boardIndependentAudit and Finance—Paid as an executive
- Jennifer SchneiderDirector · 1 yr on the boardIndependentManagement Development and Compensation—Paid as an executive
The board of the latest proxy (FY2025).
Activity
No new filings about this company in the feed.
Filings23
See all| Current report | 8-K | Oct 20, 2026 | — |
| Current report | 8-K | Sep 1, 2026 | — |
| Current report | 8-K | May 13, 2026 | — |
| Current report | 8-K | Apr 29, 2026 | — |
| Proxy statement | DEF 14A | Apr 2, 2026 | FY2025 |
| Annual report | 10-K | Feb 13, 2026 | FY2025 |